|
GSK
says heart drug darapladib fails in second late-stage trial
Send a link to a friend
[May 13, 2014]
LONDON (Reuters)
— GlaxoSmithKline said its drug darapladib had not reduced
heart attacks or other major events in patients with acute coronary
syndrome, marking another disappointment for the innovative heart
medicine.
|
|
 Darapladib had already failed in a late-stage trial
for patients with well-treated heart disease. [ID:nL1N0MR078]
Patrick Vallance, GSK’s President of Pharmaceuticals R&D, said he
was disappointed that the outcome of the second phase III study did
not support a regulatory submission.
"In the study, darapladib did not achieve the primary endpoint of a
reduction of major coronary events versus placebo when added to
standard of care," the British company said on Tuesday.
(Reporting by Paul Sandle; editing by Kate Holton)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
